上海lf已验证

first_imgLocal NewsBusiness Facebook By Digital AIM Web Support – February 19, 2021 WhatsApp Twitter Pinterest ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™ Monoclonal Antibody Cocktail Candidate Against COVID-19 Facebookcenter_img WhatsApp Twitter Pinterest TAGS  VICTORIA, British Columbia–(BUSINESS WIRE)–Feb 19, 2021– ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamsters of IPA’s proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In a preclinical study using a SARS-CoV-2 hamster model, treatment with IPA’s TATX-03 resulted in complete clearance of detectable replication-competent virus from the lungs and throat of SARS-CoV-2 infected animals. The results of the preclinical study demonstrated the potential of IPA’s TATX-03 antibody cocktail to provide strong anti-viral effects against SARS-CoV-2 in both prophylactic (preventative) and treatment settings. IPA’s TATX-03 cocktail is designed with the goal of being both protective and curative for COVID-19 disease. In addition, by incorporating multiple antibodies that recognize different, non-overlapping epitopes on the SARS-CoV-2 spike protein, IPA’s TATX-03 antibody cocktail has the potential to prevent mutational escape, the process by which a virus, through mutation, may render vaccines less efficacious. TATX-03 was 100% efficacious in the preclinical hamster model in treating SARS-CoV-2 infection in a therapeutic setting. IPA’s TATX-03 PolyTope antibody cocktail was administered as a single dose to hamsters that had been infected with the SARS-CoV-2 variant. The study showed that IPA’s antibody cocktail cleared the lungs of detectable replication-competent virus in 100% of the SARS-CoV-2 infected hamsters by day 4 post-infection. Furthermore, the study showed undetectable levels of virus titer in the throat of 100% of the infected hamsters 3 days after virus infection. TATX-03 protected against SARS-CoV-2 infection in a prophylactic setting. Administration of a single dose of IPA’s TATX-03 PolyTope antibody cocktail twenty-four hours prior to infecting hamsters with a SARS-CoV-2 variant resulted in the reduction of replication-competent virus titer to undetectable levels in the lungs of four out of five hamsters by day 4, with the remaining animal showing virus levels barely above the lowest level of detection. Mutagenic escape risk reduction by IPA’s PolyTope approach. In developing IPA’s TATX-03, the Company enrolled their PolyTope approach to facilitate cocktail formation of antibodies that recognize non-overlapping SARS-CoV-2 spike protein epitopes to improve the potential of its product to remain effective despite multiple mutations of the virus. As treatment efficacy is not solely dependent on one antibody, a combination therapy is expected to be efficacious even if one of the components would be affected by a particular virus mutation. In addition, the plug-and-play character of IPA’s PolyTope approach is anticipated to allow quick adaptation of treatment formulations, if required, leveraging their diversified lead antibody pool containing multiple antibody alternatives to each epitope represented in the cocktail. While extensive mutant analysis is ongoing, IPA has confirmed that interaction of two out of three tested antibodies from the TATX-03 cocktail with the S. African (B.1.351) and UK (B.1.1.7) SARS-CoV-2 spike protein variants is not compromised (the fourth was not prioritized for testing as, based on computational analysis, it was deemed unlikely to be impacted by the mutations). Twenty-seven extensively characterized, potently neutralizing lead candidate antibodies will be analyzed to generate full interaction profiles against seventeen different SARS-CoV-2 variants, including the S. African, Brazilian, UK and more prevalent single substitution mutants SARS-CoV-2 spike protein variants. Data are expected to be available early March. “This important preclinical study shows that TATX-03 not only protected against, but effectively treated, a high dose of SARS-CoV-2 variant infection in hamsters, further supporting the advancement of TATX-03,” stated Dr. Ilse Roodink, ImmunoPrecise’s SARS-CoV-2 Global Program Director. “Based on the positive data obtained to date, we remain optimistic about TATX-03 and its potential to prevent and treat COVID-19 disease,” added Dr. Jennifer Bath, CEO of ImmunoPrecise, “including disease caused by SARS-CoV-2 variants, as was intended in IPA’s original design of the cocktail. We are looking forward to continuing to progress TATX-03 through the final stages of its preclinical development.” IPA intends to conduct what it anticipates will be the final IND-enabling studies, including non-human primate, dose-dependent evaluation of the TATX-03 antibody cocktail, in late Q2 2021, resulting in what IPA anticipates will provide the final, necessary preclinical data points to support the potential clinical evaluation of TATX-03. About IPA’s PolyTope Platform. IPA’s SARS-CoV-2 PolyTope monoclonal therapies are designed to protect against mutagenic escape with an emphasis on efficacy for every patient, variant, and strain of SARS-CoV-2. They are created with the goal of sustainable efficacy in the face of an evolving virus, combining extensively characterized, potently neutralizing, synergistic antibodies exhibiting richly diverse epitope coverage. About ImmunoPrecise Antibodies Ltd. IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company’s therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes. For further information, visit www.immunoprecise.com or contact [email protected] Forward Looking Information This news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information contained in this news release include, but are not limited to, statements regarding the potential of IPA’s PolyTope monoclonal antibodies, including TATX-03, to provide strong anti-viral effects against SARS-CoV-2/COVID-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment, or to retain efficacy over time, or to have antibodies available to add to its PolyTope antibody cocktail to respond to new virus variants. In respect of the forward-looking information contained herein, the Company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the Company may not be successful in developing its PolyTope antibody cocktail or other vaccines or therapeutics against COVID-19 through the successful and timely completion of preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, and, be successful in partnering or commercializing its products related to COVID-19, the coverage and applicability of the Company’s intellectual property rights to its PolyTope antibody cocktails, as well as those risks discussed in the Company’s Annual Information Form dated November 16, 2020 (which may be viewed on the Company’s profile at www.sedar.com ) and the Company’s Form 40-F dated December 28, 2020 (which may be viewed on the Company’s profile at www.sec.gov ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking information contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005110/en/ CONTACT: For investor information please contact: Frédéric Chabot Phone: 1-438-863-7071 Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA CANADA INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: ImmunoPrecise Antibodies Ltd. Copyright Business Wire 2021. PUB: 02/19/2021 07:28 AM/DISC: 02/19/2021 07:28 AM http://www.businesswire.com/news/home/20210219005110/en Previous articleSokal Signs Keffer VolkswagenNext articleEaton Names Daniel Hopgood Senior Vice President and Controller Digital AIM Web Supportlast_img read more

first_imgIS IT TRUE when people get desperate they will do desperate things? …desperation can be caused by loss of employment, not able to pay your water bill, gas and electric bills, mobile phone bill, can’t pay your rent or mortgage payments, experiencing a medical issue, going through a divorce, can’t buy food or medicine, or can’t make your car payment?IS IT TRUE we are told by people in the know if some of the self-serving and narcissistic politicians don’t stop making unreasonable political promises that it could lead to civil discourse among the masses?IS IT TRUE it looks like some people living in Michigan and Kentucky are becoming somewhat desperate and are beginning to openly protest against some of the decisions and promises made by their elected officials?  …according to recent news reports, some people are beginning to feel helpless and angry about their current economic station in life?IS IT TRUE we can guarantee the next time a politician calls a news conference to talk about the COVID-19 virus they better also have a workable and well thought out plan to safely put people back to work?IS IT TRUE we are told that most people are getting sick and tired of hearing mindless platitudes making comments about how to eradicate the COVIS-19 virus?  …the comments are coming from unqualified people?…if there has ever been a time for competence (doctors, researchers, and scientists) to step forward and political charismatics to keep their mouths shut, this is the time?IS IT TRUE for over a month we watched Governors Andrew Como (NEW YORK) speak in detail on how to protect people from the Coronavirus? …he is brutally direct, honest, well informed and well-spoken? …he understands how deadly this virus can be and how to take it head-on? …it’s also obvious that he is putting ordinary citizens, first responders and health professionals above profits?IS IT TRUE we give first responders, nurses, doctors, law enforcement, health professionals, delivery persons, hospital administrators, national guard, clergy and grocery store clerks, and owners and trucks drivers five (cheers) for the brave things that they are doing to protect us during this time of crisis?IS IT TRUE that re-opening our society must be a step-by-step and gradual process by utilizing contact tracing that involves mapping whom the patient was involved with before contracting the COVID-19 disease?  …testing is also another important element in preparing to reopen our society to a normal way of life?  …that certain political types better understand that this crisis “Isn’t Over Till The Fat Lady Sings”?IS IT TRUE  recently Berry Global announced they will be temporarily laying off approximately 600 employees for one week? …foodservice products for the restaurant industry have seen a decrease in demand was the main reason for the unexpected lay-off?  …we recently predicted that the employees shouldn’t be surprised to hear that the lay-offs may be longer than originally announced?IS IT TRUE that a once gainfully employed divorced waitress with two kids told us that when she gets her $2,200 governmental stimulus check it will last like a snowball in the Sahara Desert?IS IT TRUE when the people fear the Government we have Tyranny!  When the government fears the people we have Liberty? We hope that today’s “IS IT TRUE” will provoke honest and open dialogue concerning issues that we, as responsible citizens of this community, need to address in a rational and responsible way?IS IT TRUE that Linda McMahon is the wife of the multi-millionaire owner and CEO of the World Wrestling Entertainment Corp.? …that Linda McMahon was a former Trump cabinet appointee? …last year Linda McMahon left her cabinet position with President position as Chief of the Small Business Administration to form the American First Action Super PAC? …this committee mission is to raise hundreds of millions of dollars for the “Trump For President” campaign?IS IT TRUE that the Orange County Florida Sheriff went to the World Wrestling Entertainment Performance Center numerous times in March and April to inform the owner that wrestling isn’t an essential business and needed to be shut down?  …that a few days later the Republican Florida Governor declared WWE as an essential business? …we now understand where the saying “it’s not what you know but who you know” started?IS IT TRUE the masses are finally getting fed up with the political patronage and pork-barrel politics of self-serving and narcissistic Federal, State and local politicians? IS IT TRUE as of 12 noon today only 1% of the population of the United States have been tested for the COVID-19 virus?IS IT TRUE the population of the United States is 327 million people?  …as of today, around 2 million-plus people have been tested for the virus? IS IT TRUE our “READERS POLLS” are non-scientific but trendy?Today’s “Readers Poll” question is:  Who’s more qualified in determining when people should be allowed to go back to work?Please take time and read our articles entitled “STATEHOUSE FILES, LAW ENFORCEMENT, “READERS POLL”, BIRTHDAYS, HOT JOBS”, EDUCATION, OBITUARIES and “LOCAL SPORTS”.You now are able to subscribe to get the CCO daily or If you would like to advertise on the CCO please contact us at City-County [email protected]: City-County Observer Comment Policy. Be kind to people. No personal attacks or harassment will not be tolerated and shall be removed from our site.We understand that sometimes people don’t always agree and discussions may become a little heated.  The use of offensive language, insults against commenters will not be tolerated and will be removed from our site.Any reader’s comments posted in this column do not represent the views or opinions of the City-County Observer or our advertisers FacebookTwitterCopy LinkEmailSharelast_img read more